How To Write An Effective Letter: FDA Advises Sponsors On Crafting Drug Alerts
This article was originally published in The Pink Sheet Daily
Guidance on “Dear Doctor” letters says companies should evaluate the effectiveness of their communications – but solely for their own use.
You may also be interested in...
Agency offers a sneak peek into final “Dear Health Care Provider Letters” guidance, decreasing some of industry’s burden, while refusing to cave on other requirements.
Justice Ginsburg wrote two decisions in pharmaceutical related-cases over the past decade, joined the majority in opinions on the scope of patents, and dissented in decisions giving protection to generic manufacturers and speech of pharmaceutical companies. Her death could impact the outcome of cases challenging the Affordable Care Act.
Neither has announced a firm timeline, and the difference between Pfizer's 'October' and Moderna's 'November' could be mere hours or a few weeks, but Pfizer, by dint of luck or experience, is now in a position to offer the more optimistic projection on when it will seek an EUA. Both firms release their Phase III trial protocols, which seem in line with US FDA guidance.